<DOC>
	<DOCNO>NCT00422864</DOCNO>
	<brief_summary>This trial single-arm study patient present local metastatic adenocarcinoma rectum . The aims trial ( 1 ) determine tolerability rate , ( 2 ) determine toxicity rate , pelvic distant response rate patient locally advanced rectal cancer presence distant metastasis treat interdigitating chemotherapy ( oxaliplatin/5-fluorouracil [ 5FU ] ) radiotherapy regimen .</brief_summary>
	<brief_title>A Single Arm Trial Oxaliplatin 5FU With Concurrent Radiation Patients With Metastatic Rectal Cancer</brief_title>
	<detailed_description>- Week 1 : Oxaliplatin 100 mg/m2 Day 1 ( 2 hour ) , leucovorin 200mg/m2 Day 1 concurrent oxaliplatin 2 hr , 5-FU 400mg/m2 bolus Day 1 , 5-FU continuous infusion 2.4 g/m2 46 hour Day 1 . - Weeks 3 5 : radiotherapy 25.2 Gy 14 fraction 3 week 85 mg/m2 oxaliplatin first day continuous infusion 5-FU 200 mg/m2/day day radiotherapy , - Week 6 : per Week 1 , - Weeks 8-10 : per Weeks 3-5 - Weeks 11 : per Week 1 .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Patients previously untreated pathologically proven adenocarcinoma rectum distant metastasis would benefit combined local therapy systemic chemotherapy . 2 . Lower border tumour must within 15cm anal verge . 3 . Age &gt; = 18 year . 4 . ECOG Performance Status 02 5 . Absolute Neutrophil Count &gt; 1.5x10^9/L , haemoglobin &gt; 100 g/L , platelet &gt; 100x10^9/L . 6 . Renal : Creatinine clearance &gt; = 55 mL/min ( use radioisotope renal scan derive serum creatinine use CockcroftGault formula ) . 7 . Bilirubin &lt; = 2.0 x upper limit normal . 8 . ALT &lt; = 5 x upper limit normal 9 . Life expectancy excess 3 month . 10 . No symptomatic peripheral neuropathy &gt; grade 2 . 11 . Males nonpregnant , nonlactating female . Female patient childbearing potential , surgically sterilize , must use adequate form contraception ( oral contraceptive pill barrier method ) . 12 . Signed informed consent 1 . Prior pelvic radiotherapy 2 . Febrile intercurrent illness infection . 3 . History myocardial infarction within previous six month unstable cardiac disease medical condition likely compromise safe delivery chemotherapy radiotherapy . 4 . Concurrent treatment anticancer therapy . 5 . Significant medical condition opinion investigator would compromise plan delivery chemotherapy radiotherapy may potentially exacerbated modality . 6 . Locally recurrent rectal cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>